Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Airbnb, Inc. (ABNB) vs Ascendis Pharma A/S (ASND) Price & Performance

Airbnb, Inc.Trade
Ascendis Pharma A/STrade

Price performance (Past 24H)

Key statistics

Airbnb, Inc. vs Ascendis Pharma A/S — how do they compare? Airbnb, Inc. trades at $180.59 (market cap $110.76B), while Ascendis Pharma A/S trades at $255.85 (market cap $16.67B). The key difference: Airbnb, Inc. is far larger — about 6.6× Ascendis Pharma A/S's market cap, and Airbnb, Inc. is trading nearer its 52-week high, Ascendis Pharma A/S nearer its low. Which is the better fit depends on your goals.

ABNBASND
Market Cap
$110.76B$16.67B
Sector
Consumer CyclicalHealth
52-Week High
$184.98$277.18
52-Week Low
$111.54$189.74
Enterprise Value
$101.19B$17.04B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Airbnb, Inc.

ABNB trades at $184.70, up 3.72% in 24 hours, near its 52-week high. The stock shows bullish technical signals with strong moving averages and recent earnings beat in Q2 2026. Revenue growth is steady, with 2025 revenue at $12.24 billion and net income of $2.51 billion, though Q4 2025 and Q1 2026 EPS missed expectations. Analyst sentiment is mixed with a consensus price target of $173.26, below the current price, and news highlights AI-driven growth initiatives.

Outlook is cautiously optimistic with AI expansion boosting bookings and margins, but high valuation ratios like a P/E of 42.23 pose risks. Competition and economic sensitivity are key concerns. Institutional holdings and bullish technical trends support upside potential if execution continues.

Ascendis Pharma A/S

Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.

ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Airbnb, Inc.

Airbnb, Inc. operates an online marketplace for travel information and booking services. The Company offers lodging, home stay, and tourism services via websites and mobile applications. Airbnb serves clients worldwide.

Read more on ABNB

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.

Read more on ASND